# Bimagrumab Plus Semaglutide: The Muscle Question

By Nora Bissett, Pricing Editor (https://glpwatchdog.org/authors/nora-bissett) | Published: 2026-08-19 | Updated: 2026-11-02

Canonical page: https://glpwatchdog.org/research/bimagrumab-plus-semaglutide

> The combination lost 17.8 kg at 48 weeks against 14.2 kg for semaglutide alone. But bimagrumab exists to change what you lose, and the published summary reports only how much.

## Key points

- Week 48: −17.8 kg combination, −14.2 kg semaglutide, −9.3 kg bimagrumab, −3.3 kg placebo.
- The published summary reports total weight, not the fat-versus-lean split the drug exists to change.
- Phase 2, 507 people across nine arms, and given intravenously every 12 weeks.
- Bimagrumab brings its own side effects: muscle spasms, diarrhea, acne.

If the objection to GLP-1 drugs is that they take muscle along with fat, the obvious answer is a second drug that protects muscle. Bimagrumab is that drug, and a 2026 phase 2 trial tested it alone, with semaglutide, and against placebo in 507 adults. The combination lost **17.8 kg** at 48 weeks against 14.2 kg for semaglutide alone.[1] What the published summary does not report is the number the whole idea rests on.

## What the trial found

Adults were eligible with obesity, or with overweight plus at least one obesity-associated complication. They were randomized across nine groups for 48 weeks, followed by an open-label extension to week 72. Bimagrumab is given intravenously every 12 weeks; it targets type II activin receptors, with the intent of reducing fat mass while promoting muscle growth.[1]

*Least-squares mean absolute change in body weight at week 48. All groups shown differ from placebo at p<0.001.*

| Group | Weight change |
| --- | --- |
| Placebo | −3.3 kg |
| Bimagrumab 30 mg/kg | −9.3 kg |
| Semaglutide 2.4 mg | −14.2 kg |
| **Bimagrumab 30 mg/kg + semaglutide 2.4 mg** | **−17.8 kg** |

Improvements continued through week 72. Bimagrumab’s common adverse events were muscle spasms, diarrhea and acne; semaglutide brought the familiar nausea, diarrhea, constipation and fatigue.[1]

## The number that is missing

Bimagrumab’s entire rationale is *composition*: not how much weight comes off, but what kind of tissue it is. The published summary reports total body weight and does not report the fat-versus-lean split.

> A drug designed to change what you lose, reported by how much you lose. The headline figure is not the one the hypothesis is about.

So the trial shows less than the excitement around this combination suggests. It establishes that adding bimagrumab produces more weight loss than semaglutide alone. It does not, in what has been published here, establish that the weight lost was more favorably composed, and that is the claim the drug exists to make. If you see this trial cited as proof that muscle was preserved, check whether the person citing it has a body-composition number or is assuming one.

> This matters beyond one trial. Our piece on [muscle volume versus muscle function](https://glpwatchdog.org/research/muscle-volume-versus-muscle-function) found lean mass falling 9.3% while physical performance edged *up*. Even a real composition benefit would still need to show that it changes what someone can do. Mass is the easy measurement; function is the point.

## What this is and is not, practically

- **Phase 2, not phase 3.** 507 people across nine arms means each arm is small, and phase 2 results routinely shrink when tested properly.
- **An intravenous infusion every 12 weeks.** This is not a pen you take home. It changes cost, access and who realistically receives it.
- **Not available, and not close.** Nobody can prescribe this combination outside a trial, and no compounder can lawfully supply it (see [what cannot legally be compounded](https://glpwatchdog.org/research/what-cannot-legally-be-compounded)).
- **New adverse events, not just more of the old ones.** Muscle spasms and acne are bimagrumab’s, not semaglutide’s.

The direction is interesting. Combination therapy aimed at composition rather than scale weight is where obesity medicine is going, and bimagrumab is not the only candidate: [apitegromab has been tested alongside tirzepatide](https://glpwatchdog.org/research/a-drug-to-protect-muscle). This is a real trial, and the result is a real one. It is also a phase 2 result, and a phase 3 program would have to confirm it before it means anything to a reader.

## Frequently asked questions

### Does bimagrumab prevent muscle loss on a GLP-1?

That is the hypothesis, and the published summary of this trial does not report the fat-versus-lean split needed to confirm it. What it reports is total weight: 17.8 kg lost on the combination against 14.2 kg on semaglutide alone. Treat any claim that muscle was preserved as needing a number that this summary does not provide.

### How much more weight did the combination take off?

At 48 weeks, the high-dose combination lost 17.8 kg against 14.2 kg for semaglutide 2.4 mg alone, 9.3 kg for bimagrumab alone and 3.3 kg for placebo. Improvements continued through a week-72 extension.

### Can I get this?

No. It is a phase 2 trial result, bimagrumab is not approved, and it comes as an intravenous infusion every 12 weeks rather than as a pen. No compounder can lawfully supply it either.

### What are the side effects of adding it?

Bimagrumab's common adverse events in this trial were muscle spasms, diarrhea and acne, a different set from semaglutide's nausea, diarrhea, constipation and fatigue. Adding a drug adds its own profile rather than simply amplifying the first.

### Is combination therapy the future for obesity?

It is clearly the direction of research, and aiming at body composition rather than scale weight is a more sophisticated target than the field has used so far. Phase 2 results routinely shrink in phase 3, so the reasonable stance is interest rather than expectation.

## References

1. Heymsfield SB, Aronne LJ, Montgomery P, et al. Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial. Nature Medicine. 2026. PMID: 41772149. https://pubmed.ncbi.nlm.nih.gov/41772149/

---

Cite as: GLP Watchdog, Nora Bissett, "Bimagrumab Plus Semaglutide: The Muscle Question", published 2026-08-19, updated 2026-11-02. https://glpwatchdog.org/research/bimagrumab-plus-semaglutide

Canonical HTML page: https://glpwatchdog.org/research/bimagrumab-plus-semaglutide

Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.
